L antigen family member 3Genealiases: CVG5 · DXS9879E · DXS9951E · ESO3 · GAMOS2 · ITBA2
Q-omics provides the consensus-scored LAGE3 profile across patient tissues and cancer cell-line models. LAGE3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LAGE3 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, LAGE3 RNA expression shows 18,756 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where LAGE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAGE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAGE3 survival associations across molecular data types. LAGE3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAGE3 RNA expression–survival associations across cancer types. High LAGE3 expression shows unfavorable associations in KIRP, KICH, KIRC, LIHC and LGG, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LAGE3 RNA expression.
This table summarizes LAGE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LAGE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAGE3 shows higher tumor expression in HNSC, COAD, BLCA, LIHC, STAD and LUAD. The HNSC box plot shows higher LAGE3 RNA expression in tumor versus normal tissue (log2 FC = +1.256, t-test p < 0.001).
This table shows molecular features associated with LAGE3 in patient tissues and cancer cell lines. In patient samples, LAGE3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LAGE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
